Vittamed is a commercial stage neurodiagnostic company based in the Boston area with research and manufacturing operations in Lithuania. Vittamed has developed a platform of innovative noninvasive devices: Vittamed 205 non-invasive intracranial pressure (ICP) system that does not require patient specific calibration; and Vittamed 505 non-invasive bedside monitor for assessing cerebrovascular autoregulation. Both devices have CE Mark approval.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 10/19/15 | $10,000,000 | Series A |
Xeraya Capital | undisclosed |
